Results 221 to 230 of about 89,895 (292)

Adalimumab as a Potential Therapeutic Option for Metastatic Crohn's Disease With Genital Lesions and Edema: A Case Report. [PDF]

Clin Case Rep
Haghshenas H, Darban B, Bagherzadeh MA, Karimi M, Ataollahi M.   +4 more
europepmc   +1 more source

A Population‐Based Matched Cohort Study of Extra‐Digestive Cancer Incidence and Mortality in Individuals With and Without Inflammatory Bowel Disease

Alimentary Pharmacology &Therapeutics, EarlyView.
This illustration summarises our primary findings highlighting the rising incidence of certain extra‐digestive cancers among persons with IBD over the 25‐year study duration (left), and the relative rates of extra‐digestive cancer incidence and mortality among persons with IBD in recent years (2010–2019) compared to their age‐ and sex‐matched controls (
Sanjay K. Murthy, Faria Ahmed, Michael Pugliese, Monica Taljaard, Parul Tandon, Priscilla Matthews, Gilaad G. Kaplan, Stephanie Coward, Charles N. Bernstein, Eric I. Benchimol, M. Ellen Kuenzig, Laura E. Targownik, Harminder Singh, on behalf of the Canadian Gastro‐Intestinal Epidemiology Consortium (CanGIEC)   +13 more
wiley   +1 more source

Clinically differentiating Behcet's syndrome from Crohn's disease. [PDF]

JRSM Open
Stone CJ, Ali H, On A, Roberts WN.
europepmc   +1 more source

Intestinal Ultrasound Transmural Healing Was Associated With Improved Long‐Term Outcomes Among Patients With Endoscopic Remission: Results of a Prospective Study

Alimentary Pharmacology &Therapeutics, EarlyView.
This a prospective study showing the benefit of intestinal ultrasound transmural healing on long term outcome among patient with partial and complete endoscopic healing in Crohn's disease. ABSTRACT Background STRIDE II guidelines recognise endoscopic healing as a main therapeutic target in Crohn's disease (CD).
Clara Yzet, Amélie Plancke, Franck Brazier, Lucien Grados, Elise Derval, Louise Ghilardi, Momar Diouf, Adrien Ollier, Mathurin Fumery   +8 more
wiley   +1 more source

Non-fistulous Bladder Ulceration in Crohn's Disease: A Rare Extraintestinal Manifestation. [PDF]

Cureus
Jazzar A, Beydoun S, Hallal M, Alameh W.
europepmc   +1 more source

Atypical Clinical Presentation of Crohn's Disease with Superior Mesenteric Vein Obstruction and Protein-losing Enteropathy

, 2018
Suguru Ito, Masaaki Higashiyama, Kazuki Horiuchi, Akinori Mizoguchi, Shigeyoshi Soga, Rina Tanemoto, Shin Nishii, H Terada, Akinori Wada, Nao Sugihara, Yoshinori Hanawa, Hirotaka Furuhashi, Takeshi Takajo, Kazuhiko Shirakabe, Chikako Watanabe, Shunsuke Komoto, Kengo Tomita, Shigeaki Nagao, Masami Shinozaki, Akihiko Nakagawa, Michio Kubota, Daisuke Miyagishima, Nobuaki Gotoh, Soichiro Miura, Hideki Ueno, Ryota Hokari   +25 more
openalex   +2 more sources

Serum Villin‐1—A Novel Marker of Gut Barrier Damage in Acutely Decompensated Cirrhosis: A Cohort Study and Validation

Alimentary Pharmacology &Therapeutics, EarlyView.
Serum villin‐1 is a non‐invasive indicator of gut barrier damage and short‐term mortality in acutely decompensated cirrhosis. Incorporating villin‐1 assessment into risk stratification methods improves prognostic accuracy by capturing an essential, yet previously overlooked component of disease progression.
David Tornai, Boglarka Balogh, Aniko Csillag, Andras Budai, Andras Kiss, Peter Antal‐Szalmas, Gabor Mehes, Lukacs Barath, Tamas Tornai, Istvan Tornai, Zsuzsanna Vitalis, Nora Sipeki, Tamas Dinya, Attila Enyedi, Florian A. Rosenberger, Wim Laleman, Minneke J. Coenraad, Ferran Aguilar, Joan Claria, Richard Moreau, Jonel Trebicka, Maria Papp, on behalf of MICROB‐PREDICT and PREDICT study group of the EASL‐CLIF consortium   +22 more
wiley   +1 more source

Adverse events associated with ustekinumab in Crohn's disease treatment: an analysis based on the FAERS database. [PDF]

Front Med (Lausanne)
Guo C, Zhao S.
europepmc   +1 more source

Meta‐Analysis: Prevalence of Eating Disorders in Inflammatory Bowel Disease

Alimentary Pharmacology &Therapeutics, EarlyView.
Eating disorders are common among individuals with IBD, with prevalence estimates ranging from 3% to 14% depending on the assessment method. Findings highlight the need for validated screening tools tailored to IBD. ABSTRACT Background and Aims Disentangling whether disordered eating is a cause, consequence or manifestation of inflammatory bowel ...
Quinn Goddard, Ante Markovinović, Paul E. Ronksley, Cynthia H. Seow, Christopher Ma, Abdel‐Aziz Shaheen, Gilaad G. Kaplan   +6 more
wiley   +1 more source